Two Sigma Advisers LP lessened its position in shares of ConforMIS Inc (NASDAQ:CFMS) by 10.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 139,400 shares of the medical instruments supplier’s stock after selling 15,500 shares during the quarter. Two Sigma Advisers LP owned approximately 0.22% of ConforMIS worth $50,000 as of its most recent filing with the Securities and Exchange Commission.
Other large investors have also recently made changes to their positions in the company. Acadian Asset Management LLC lifted its position in shares of ConforMIS by 26.0% during the 4th quarter. Acadian Asset Management LLC now owns 127,166 shares of the medical instruments supplier’s stock worth $45,000 after buying an additional 26,202 shares during the period. Vanguard Group Inc lifted its position in shares of ConforMIS by 1.3% during the 3rd quarter. Vanguard Group Inc now owns 2,230,254 shares of the medical instruments supplier’s stock worth $2,364,000 after buying an additional 28,556 shares during the period. Gabelli Funds LLC lifted its position in shares of ConforMIS by 76.2% during the 4th quarter. Gabelli Funds LLC now owns 104,056 shares of the medical instruments supplier’s stock worth $37,000 after buying an additional 45,000 shares during the period. Finally, Renaissance Technologies LLC lifted its position in shares of ConforMIS by 10.0% during the 3rd quarter. Renaissance Technologies LLC now owns 3,306,461 shares of the medical instruments supplier’s stock worth $3,505,000 after buying an additional 299,561 shares during the period. 30.35% of the stock is currently owned by institutional investors.
Shares of CFMS stock traded down $0.07 on Wednesday, reaching $3.37. 539,443 shares of the stock were exchanged, compared to its average volume of 1,339,134. The company has a market cap of $233.45 million, a P/E ratio of -4.55 and a beta of 3.05. ConforMIS Inc has a one year low of $0.36 and a one year high of $3.84. The company has a quick ratio of 2.33, a current ratio of 3.00 and a debt-to-equity ratio of 0.64.
ConforMIS (NASDAQ:CFMS) last released its earnings results on Wednesday, May 1st. The medical instruments supplier reported ($0.12) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.12). The company had revenue of $20.64 million during the quarter, compared to the consensus estimate of $20.11 million. ConforMIS had a negative return on equity of 97.85% and a negative net margin of 42.90%. As a group, equities research analysts anticipate that ConforMIS Inc will post -0.43 earnings per share for the current fiscal year.
In related news, CEO Mark A. Augusti sold 25,477 shares of ConforMIS stock in a transaction on Tuesday, May 7th. The stock was sold at an average price of $2.72, for a total transaction of $69,297.44. Following the completion of the sale, the chief executive officer now directly owns 1,123,698 shares of the company’s stock, valued at $3,056,458.56. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CFO Paul S. Weiner sold 12,612 shares of ConforMIS stock in a transaction on Tuesday, May 7th. The stock was sold at an average price of $2.72, for a total value of $34,304.64. Following the sale, the chief financial officer now directly owns 568,629 shares of the company’s stock, valued at $1,546,670.88. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 80,801 shares of company stock valued at $222,106. 3.38% of the stock is owned by insiders.
Several equities analysts have issued reports on CFMS shares. Oppenheimer set a $4.00 price objective on ConforMIS and gave the company a “buy” rating in a research report on Thursday, May 2nd. BTIG Research reiterated a “buy” rating and issued a $3.00 price objective on shares of ConforMIS in a research report on Thursday, May 2nd. Finally, Zacks Investment Research upgraded ConforMIS from a “hold” rating to a “buy” rating and set a $2.50 price objective for the company in a research report on Wednesday, April 10th. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $3.00.
TRADEMARK VIOLATION WARNING: “ConforMIS Inc (CFMS) Shares Sold by Two Sigma Advisers LP” was first published by Sundance Herald and is owned by of Sundance Herald. If you are accessing this piece on another site, it was illegally copied and reposted in violation of United States and international trademark and copyright legislation. The original version of this piece can be viewed at https://sundanceherald.com/2019/05/22/conformis-inc-cfms-position-cut-by-two-sigma-advisers-lp.html.
Conformis, Inc, a medical technology company, develops, manufactures, and sells joint replacement implants. The company offers customized knee replacement products, including iTotal CR, a cruciate-retaining product; iTotal PS, a posterior cruciate ligament substituting product; iDuo, a customized bicompartmental knee replacement system; and iUni, a customized unicompartmental knee replacement product to treat the medial or lateral compartment of the knee.
Featured Article: Day Trading – Risk Worth the Reward?
Receive News & Ratings for ConforMIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ConforMIS and related companies with MarketBeat.com's FREE daily email newsletter.